Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRM Mirum Pharmaceuticals, Inc.

Market Closed 04-02 16:00:00 EDT

94.17

-0.45

-0.48%

盘后94.17

+0.000.00%

16:20 EDT

High95.14	Low92.37	Vol742.95K
Open93.64	D1 Closing94.62	Amplitude2.93%
Mkt Cap5.68B	Tradable Cap3.77B	Total Shares60.34M
T/O69.68M	T/O Rate1.86%	Tradable Shares39.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRM","market":"US","secType":"STK","nameCN":"Mirum Pharmaceuticals, Inc.","latestPrice":94.17,"timestamp":1775160000000,"preClose":94.62,"halted":0,"volume":742948,"hourTrading":{"tag":"盘后","latestPrice":94.17,"preClose":94.17,"latestTime":"16:20 EDT","volume":38570,"amount":3632136.9,"timestamp":1775161200508,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.004755865567533321,"floatShares":39985740,"shares":60341617,"eps":-0.47,"marketStatus":"Market Closed","change":-0.45,"latestTime":"04-02 16:00:00 EDT","open":93.64,"high":95.14,"low":92.37,"amount":69680063.34144,"amplitude":0.029275,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.47,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":94.62,"preHourTrading":{"tag":"盘前","latestPrice":93.5,"preClose":94.62,"latestTime":"09:25 EDT","volume":150,"amount":14113.20075,"timestamp":1775136339622,"change":-1.12,"changeRate":-0.011837,"amplitude":0.036779},"postHourTrading":{"tag":"盘后","latestPrice":94.17,"preClose":94.17,"latestTime":"16:20 EDT","volume":38570,"amount":3632136.9,"timestamp":1775161200508,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5860297452927176,"impliedVol":0.8531,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/MIRM/tweets","defaultTab":"tweets","newsList":[{"id":"2623602589","title":"Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi Year Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2623602589","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623602589?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:17","pubTimestamp":1774952240,"startTime":"0","endTime":"0","summary":"Wondering if Mirum Pharmaceuticals at around US$87.90 is still offering value after a strong run, or if most of the opportunity is already reflected in the price.\nThe stock has been flat over the past week, recorded a 4.8% decline over the last 30 days, yet is up 12.6% year to date and 99.6% over the past year, with a very large 3 year gain of 252.3% and a 5 year gain of 340.6%.\nRecent coverage has focused on Mirum Pharmaceuticals as a fast moving biotech name. This helps frame why the share...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/is-it-too-late-to-consider-mirum-pharmaceuticals-mirm-after-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/is-it-too-late-to-consider-mirum-pharmaceuticals-mirm-after-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","FCF","BK4211","DCF","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621848770","title":"Mirum Pharmaceuticals Price Target Maintained With a $130.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2621848770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621848770?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:10","pubTimestamp":1774264200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 07:10 ET (11:10 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620019764","title":"Mirum Pharmaceuticals Director Saira Ramasastry Disposes of USD 181,520 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620019764","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620019764?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:30","pubTimestamp":1773790254,"startTime":"0","endTime":"0","summary":"Saira Ramasastry, Director at Mirum Pharmaceuticals, reported a disposal of 2,000 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4zClXl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mirum Pharmaceuticals Director Saira Ramasastry Disposes of USD 181,520 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619468295","title":"Mirum Pharmaceuticals Completes Enrollment In Phase 3 Expand Study Of Livmarli® (Maralixibat) In Additional Rare Cholestatic Liver Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468295","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468295?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:23","pubTimestamp":1773663803,"startTime":"0","endTime":"0","summary":"March 16 (Reuters) - Mirum Pharmaceuticals Inc ::*MIRUM PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 EXPAND STUDY OF LIVMARLI (MARALIXIBAT) IN ADDITIONAL RARE CHOLESTATIC LIVER DISEASES*MIRUM PHARM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nRSDfVrN8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619846893","title":"Mirum Pharmaceuticals Inc - Topline Data From Expand Study Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619846893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619846893?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:00","pubTimestamp":1773662404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA8FFK6S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618983959","title":"Santhera appoints Marc Clausse as Chief Commercial Officer effective June 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618983959","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618983959?lang=en_us&edition=fundamental","pubTime":"2026-03-10 13:01","pubTimestamp":1773118913,"startTime":"0","endTime":"0","summary":"Santhera appointed Marc Clausse as chief commercial officer, effective June 1, 2026. Clausse previously served as VP of International Strategy & Operations and UK general manager at Mirum Pharmaceuticals. He will succeed Geert Jan van Daal, who will retire after 11 years at the company and support the transition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Santhera Pharmaceuticals Holding AG published the original content used to generate this news brief on March 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL1ywWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618676574","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mirum Pharmaceuticals (MIRM) and Talkspace (TALK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618676574","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618676574?lang=en_us&edition=fundamental","pubTime":"2026-03-10 01:50","pubTimestamp":1773078610,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mirum Pharmaceuticals (MIRM – Research Report) and Talkspace (TAL...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-mirum-pharmaceuticals-mirm-and-talkspace-talk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-mirum-pharmaceuticals-mirm-and-talkspace-talk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","TALK","BK4503","TAL","BK4204","BK4139","BK4137","BK4526","BK4585","BK4531","LABU","LU0128526141.USD","XLV","LU1880383366.USD","BK4196","BK4581","BK4510","BK4548","XBI","HCSG","MIRM","BK4506","LU1880383440.USD","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617852839","title":"Mirum completes enrollment in AZURE-1 study, screening in AZURE-4 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2617852839","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617852839?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:38","pubTimestamp":1772717907,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals (MIRM) announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 stu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mirum-completes-enrollment-in-azure-1-study-screening-in-azure-4-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mirum-completes-enrollment-in-azure-1-study-screening-in-azure-4-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617547994","title":"BRIEF-Mirum Pharmaceuticals Provides Azure Clinical Program Update For Brelovitug In Chronic Hepatitis Delta Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=2617547994","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617547994?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:03","pubTimestamp":1772715785,"startTime":"0","endTime":"0","summary":"BRIEF-Mirum Pharmaceuticals Provides Azure Clinical Program Update For Brelovitug In Chronic Hepatitis Delta VirusMarch 5 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O:MIRUM PHARMACEUTICALS PROVIDES AZ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3DHNFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617547124","title":"Mirum Completes AZURE-1 Enrollment and AZURE-4 Screening for Brelovitug in Chronic HDV","url":"https://stock-news.laohu8.com/highlight/detail?id=2617547124","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617547124?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:01","pubTimestamp":1772715693,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals said enrollment is complete in its Phase 3 AZURE-1 study and screening is complete in its Phase 3 AZURE-4 study evaluating brelovitug for chronic hepatitis delta virus. The company said these milestones support expected timing of topline 24-week data in the second half of 2026, with interim data from AZURE-1 expected in the second quarter. Mirum said AZURE-1 and AZURE-4 will form the basis of its planned U.S. biologics license application submission for brelovitug, which has FDA Breakthrough Therapy designation, and it reiterated an expectation for a potential U.S. BLA submission and launch in 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1N9bl9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617547503","title":"Mirum Pharmaceuticals Inc - Topline Azure-1 and Azure-4 Data Expected in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2617547503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617547503?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:00","pubTimestamp":1772715603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3DHNFK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617547349","title":"Mirum Pharmaceuticals Provides Azure Clinical Program Update for Brelovitug in Chronic Hepatitis Delta Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=2617547349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617547349?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:00","pubTimestamp":1772715603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3DHNFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617354764","title":"Mirum Pharmaceuticals Inc: Potential Bla Submission and Launch in U.S. for Azure-1 and Azure-4  Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2617354764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617354764?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:00","pubTimestamp":1772715603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3DHNFK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109433891","title":"Stock Track | Mirum Pharmaceuticals Soars 5.07% Intraday After Evercore Raises Price Target on Upcoming Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1109433891","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109433891?lang=en_us&edition=fundamental","pubTime":"2026-03-05 03:09","pubTimestamp":1772651362,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. (MIRM) saw its stock soar 5.07% during intraday trading on Wednesday, driven by positive analyst sentiment.The surge follows Evercore ISI raising its price target on the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617762550","title":"Mirum Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2617762550","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617762550?lang=en_us&edition=fundamental","pubTime":"2026-03-05 01:56","pubTimestamp":1772646960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 12:56 ET (17:56 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616554932","title":"BUZZ-Mirum Pharma gains after Evercore raises PT on liver drugs potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2616554932","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616554932?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:56","pubTimestamp":1772639781,"startTime":"0","endTime":"0","summary":"BUZZ-Mirum Pharma gains after Evercore raises PT on liver drugs potential  ** Shares of Mirum Pharmaceuticals MIRM.O rise 2.15% to $89.69 ** Evercore ISI raises PT to $126 from $101 and reiterates an \"outperform\" rating** MIRM \"checks all the boxes\" with its growing rare-liver disease portfolio plus upcoming data from multiple key trials, clear competitive outlooks, and a real margin expansion story, says Evercore analyst Gavin Clark-Gartner ** MIRM expects mid-stage data for experimental liver disease drug volixibat and interim late-stage data for hepatitis D drug candidate brelovitug in Q2 2026** Brokerage expects global unadjusted peak sales of $1.2 billion for volixibat in primary sclerosing cholangitis, a rare, chronic, progressive liver disease ** MIRM shares rose over 91% in 2025   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL4N3ZS166:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614695009","title":"Mirum Pharmaceuticals (MIRM) Narrowing Losses Challenge Bearish Profitability Narratives In FY 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2614695009","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614695009?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:31","pubTimestamp":1772155887,"startTime":"0","endTime":"0","summary":"FY 2025 results snapshot\nMirum Pharmaceuticals (MIRM) has wrapped up FY 2025 with Q4 revenue of US$148.9 million and a basic EPS loss of US$0.11, alongside trailing twelve month revenue of US$521.3 million and a full year basic EPS loss of US$0.47. Over recent quarters the company has seen revenue move from US$99.4 million in Q4 2024 to US$148.9 million in Q4 2025, while quarterly basic EPS has ranged between a loss of US$0.50 in Q4 2024 and a small profit of US$0.06 in Q3 2025. This latest...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-narrowing-losses-challenge-bearis","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-narrowing-losses-challenge-bearis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614102768","title":"Mirum Pharmaceuticals Down Over 14%, on Pace for Largest Percent Decrease Since December 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2614102768","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614102768?lang=en_us&edition=fundamental","pubTime":"2026-02-27 02:16","pubTimestamp":1772129760,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc.  is currently at $92.66, down $15.96 or 14.69%. --Would be lowest close since Jan. 20, 2026, when it closed at $91.89. --On pace for largest percent decrease since Dec. 18, 2023, when it fell 15.87%. --Down 10.23% month-to-date; on pace for worst month since Dec. 2024, when it fell 10.54%. --Down 14.69% from its all-time closing high of $108.62 on Feb. 25, 2026. --Up 97.25% from 52 weeks ago , when it closed at $46.98. --Up 141.36% from its 52-week closing low of $38.39 on April 21, 2025. --Traded as low as $90.26; lowest intraday level since Jan. 20, 2026, when it hit $89.47","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148827858","title":"Stock Track | Mirum Pharmaceuticals Plummets 11.13% Intraday Amid Mixed Analyst Sentiment and RBC Price Target Cut","url":"https://stock-news.laohu8.com/highlight/detail?id=1148827858","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148827858?lang=en_us&edition=fundamental","pubTime":"2026-02-26 23:17","pubTimestamp":1772119052,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals, Inc. (MIRM) experienced a significant intraday plummet of 11.13% on Thursday, extending losses from pre-market trading.The sharp decline follows mixed analyst sentiment toward...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614254760","title":"Mirum Pharmaceuticals sees FY26 global net product sales $630M-$650M","url":"https://stock-news.laohu8.com/highlight/detail?id=2614254760","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614254760?lang=en_us&edition=fundamental","pubTime":"2026-02-26 23:06","pubTimestamp":1772118409,"startTime":"0","endTime":"0","summary":"10:06 EST Mirum Pharmaceuticals (MIRM) sees FY26 global net product sales $630M-$650M Published first on TheFly – the ultimate source for real-time...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-sees-fy26-global-net-product-sales-630m-650m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mirum-pharmaceuticals-sees-fy26-global-net-product-sales-630m-650m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MIRM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirumpharma.com","stockEarnings":[{"period":"1week","weight":0.0595},{"period":"1month","weight":0.0726},{"period":"3month","weight":0.2062},{"period":"6month","weight":0.2909},{"period":"1year","weight":1.0927},{"period":"ytd","weight":0.1922}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.06611},{"month":2,"riseRate":0.714286,"avgChangeRate":0.037723},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.043043},{"month":4,"riseRate":0.571429,"avgChangeRate":0.05346},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.035958},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097654},{"month":7,"riseRate":0.666667,"avgChangeRate":0.076249},{"month":8,"riseRate":0.714286,"avgChangeRate":0.107618},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.04362},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.10761},{"month":11,"riseRate":0.714286,"avgChangeRate":0.084664},{"month":12,"riseRate":0.571429,"avgChangeRate":0.315468}],"exchange":"NASDAQ","name":"Mirum Pharmaceuticals, Inc.","nameEN":"Mirum Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mirum Pharmaceuticals, Inc.(MIRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mirum Pharmaceuticals, Inc.,MIRM,Mirum Pharmaceuticals, Inc.股票,Mirum Pharmaceuticals, Inc.股票老虎,Mirum Pharmaceuticals, Inc.股票老虎国际,Mirum Pharmaceuticals, Inc.行情,Mirum Pharmaceuticals, Inc.股票行情,Mirum Pharmaceuticals, Inc.股价,Mirum Pharmaceuticals, Inc.股市,Mirum Pharmaceuticals, Inc.股票价格,Mirum Pharmaceuticals, Inc.股票交易,Mirum Pharmaceuticals, Inc.股票购买,Mirum Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mirum Pharmaceuticals, Inc.(MIRM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mirum Pharmaceuticals, Inc.(MIRM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction